[S29] The consideration of the ideal form of PMDA's review reports as drug information —from the perspectives of the regulatory authorities, medical institutions, and industries—

1:55 PM - 2:10 PM JST(4:55 AM - 5:10 AM UTC)

[S29-4] Issues and expectations regarding the review reports based on surveys conducted within the Japan Pharmaceutical Manufacturers Association

○Tadashi Ishihara^1,2 (1. 日本製薬工業協会, 2. Bayer Yakuhin)